The FDA has on 31 July 2014 approved Striverdi Respimat (olodaterol) inhalation spray from Boehringer to treat patients with Chronic...
Data from the Phase III clinical program show the use of Striverdi Respimat (olodaterol), from Boehringer, provided improvements in lung...
Three EU countries have approved the use of Striverdi Respimat (olodaterol), from Boehringer Ingelheim, for patients with Chronic Obstructive Pulmonary...
Boehringer presented data from the ANHELTO 1&2 studies (NCT01694771/NCT01696058) that evaluated the co-administration of Spiriva HandiHaler (tiotropium bromide inhalation powder)...
Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).
Boehringer Ingelheim announced that the FDA approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray as a long-term, once-daily...
Boehringer Ingelheim has announced new data that show increase in FEV1 AUC0–12, a measure of lung function, with Stiolto Respimat...
The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined in a dossier assessment whether the fixed-dose...
Novartis has filed a new drug application (NDA) at the FDA for once a day Seebri Breezhaler (NVA 237) (glycopyrronium...